Company intelligence / Profile preview

NeoBiotechnologies

Ownership: Private
Development stage: Commercial

Overview

NeoBiotechnologies manufactures and supplies over 10,000 highly validated monoclonal and recombinant antibodies for research applications. Their products are widely used by researchers and scientific institutions globally. The company emphasizes strict quality assurance with a high rejection rate for subpar products.

Therapeutic areas: Other
Modalities: Monoclonal antibodiesRecombinant antibodiesMulticlonal antibodies
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on NeoBiotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeoBiotechnologies.

Explore the full profile